top of page
Logo MAAsiRNA
siRNA therapeutics, nanoparticles, siRNA-SQ, squalene

Our mission

A significant challenge in the field of nervous system pathologies lies in the absence of effective treatments. MAAsiRNA develops a pioneering targeted therapy utilizing small interfering RNA (siRNA).

After over a decade of intensive interdisciplinary research, we have successfully developed a siRNA-based treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), the most prevalent form of hereditary peripheral neuropathy. CMT1A affects 1 in 5000 people, comprising a total of 1.5 million individuals worldwide.

Our current objective is to advance towards a patient-ready therapy.

Our innovative therapeutic approach has the potential to be adapted for other disorders within the nervous system.

The founders

Antoine BAROUKY

Antoine Barouky

CEO

  • Grey LinkedIn Icon
LM.png

Liliane Massade, PhD

Expert in siRNA, nanotechnologies & oncology

  • Grey LinkedIn Icon
Charbel MASSAAD

Charbel Massaad, PhD

Expert in pathologies of nervous system

  • Grey LinkedIn Icon
David ADAMS

David Adams, PhD, MD

Expert in siRNA Clinical trials

  • Grey LinkedIn Icon

MAAsiRNA

1 Rue Du Belvédère

91120, Palaiseau, France

Contact us ! 

Thank you for your message

© 2023 par MAAsiRNA.

bottom of page